Nautilus Biotechnology Announces 2026 Annual Meeting Results and Election of Directors

Nautilus Biotechnology, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. During the meeting, stockholders elected two Class II directors, Parag Mallick and Farzad Nazem, to serve until the 2029 annual meeting. Additionally, the appointment of PricewaterhouseCoopers LLP as the company\'s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Stockholders also approved, on an advisory basis, the compensation of the company\'s named executive officers for the fiscal year ended December 31, 2025. Furthermore, an advisory vote on the frequency of future executive compensation votes resulted in a preference for an annual frequency ("1-Year"). In response, the company has determined to hold future advisory votes on executive compensation every year until the next required frequency vote, which is scheduled to occur no later than the 2032 annual meeting. A total of 85,002,191 shares were represented at the meeting, representing approximately 67% of the shares outstanding as of the record date.